The Report analyzes 43 issued U.S. patents, including processes for culturing MSCs ex-vivo, compositions comprising MSCs, and therapeutic uses for MSCs. The Report features detailed independent claim charts of the Osiris patents, as well as a single-view "portfolio" claim chart that presents this information . The claim charts, prepared by patent attorneys expert in the stem cell arts, are organized by functional claim limitations as well as therapeutic applications, providing researchers, patent attorneys and business analysts with a robust, reliable, accurate and readily comprehensible guide to the Osiris stem cell portfolio.

Stem cells are particularly attractive for use as cellular therapies because they self-renew and have the capacity to produce many different specialized cell types. In contrast to the controversial use of embryonic stem cells (ESCs), MSCs are derived from the bone marrow of adult donors.

Daniel A. Halpern, President of Sunlight Research observed, "Osiris is a key player in stem cell therapies, it has developed a leading patent portfolio, and has collaboration agreements with Genzyme, the U.S. Department of Defense and the Juvenile Diabetes Research Foundation. Understanding the strengths and limitations of Osiris' intellectual property is critical for those competing in this space." Osiris reported $40.0 million in revenue last year from its collaboration agreement with Genzyme. Halpern added that "industry professionals involved in patents, licensing, business development, investment analysis and others interested in the evolving stem cell therapy sector or concerned about patent infringement risk and competitive threats in this field will find this to be a valuable resource."

Sunlight's Osiris Stem Cell Patent report includes a detailed breakdown of claim limitations pertaining to composition, therapy, cellular, and manufacturing processes. The report provides insights into strengths and limitations of Osiris' patent coverage, and opportunities for follow-on or competing products.

The Report is delivered in PDF and Excel formats and includes an Interactive Infringement Clearance Chart, a Frequency and Type of Claim Limitation chart and a First Occurrence Claim Chart. The interactive charts allow decision-makers to perform real-time What If? Analyses.

The Report, together with a larger Stem Cell Patent Report covering all US patents relating to stem cell technologies, will be the subject of a Webinar to be held March 3, 2010 at 12:00pm CST. Please register here: https://www2.gotomeeting.com/register/616100667

Your comments are automatically posted once they are submitted. All comments are however constantly reviewed for spam and irrelevant material (such as product or personal advertisements, email addresses, telephone numbers and website address). Such insertions do not conform to our policy and 'Terms of Use' and are either deleted or edited and republished.Please keep your comments brief and relevant.This section may also have questions seeking help. If you have the information you are welcome to respond, but please ensure that the information so provided is genuine and not misleading.

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.Full Disclaimer